|
MARKETWATCH
Confidentiality Laws And Secrecy In Medical Research: Improving Public Access To Data On Drug Safety
Aaron S. Kesselheim and
Michelle M. Mello
Pharmaceutical manufacturers have long considered results collected from drugs’ clinical trials to be confidential information or trade secrets, even after submission to the Food and Drug Administration (FDA). We describe FDA policies regarding disclosure of clinical trial data and evaluate how courts have interpreted the Freedom of Information Act in cases seeking access to unreleased information. Recent examples of approved drugs later found to have dangerous side effects show the importance of complete dissemination of safety information. We suggest regulatory and legislative policy changes regarding how the FDA handles confidential information that can improve understanding of the risks of prescription drugs.
       What's this?
This article has been cited by other articles:
|
|
|
|
 
P. E. French and D. Goodman
The New Mental Health Parity Law: Issues and Concerns for Public and Private Sector Employers
Review of Public Personnel Administration,
June 1, 2009;
29(2):
189 - 196.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. J.J. Wood
Progress and Deficiencies in the Registration of Clinical Trials
N. Engl. J. Med.,
February 19, 2009;
360(8):
824 - 830.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. S. Kesselheim and J. Avorn
Pharmaceutical Promotion to Physicians and First Amendment Rights
N. Engl. J. Med.,
April 17, 2008;
358(16):
1727 - 1732.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A. Brennan and M. M. Mello
Sunshine Laws and the Pharmaceutical Industry
JAMA,
March 21, 2007;
297(11):
1255 - 1257.
[Full Text]
[PDF]
|
|
|
|
